Skip to main content

Table 2 Characteristics of all reports for the 58 antidepressant drugs of interest in VigiBase® (n = 1,027,405)

From: Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database

Characteristics

N

%

Age group

 5-17a

20,174

1.96

 18–44

252,790

24.60

 45–64

281,177

27.37

 65–74

94,779

9.23

  ≥ 75

79,894

7.78

 Unknown

298,591

29.06

Sex group

 Male

309,665

30.14

 Female

665,950

64.82

 Unknown

51,790

5.04

WHO reporting area

 Africa

3507

0.34

 Americas

  United States

594,543

57.87

  Canada

44,079

4.29

  Other countries

5549

0.54

 Asia

  China

9827

0.96

  India

8284

0.81

  Japan

7722

0.75

  Singapore

1012

0.10

  South Korea

15,919

1.55

  Other countries

5863

0.57

Europe

  France

45,142

4.39

  Germany

36,334

3.54

  Italy

16,180

1.57

  United Kingdom

99,131

9.65

  Other countries

97,238

9.46

 Oceania

  Australia

30,210

2.94

  New Zealand

6865

0.67

Notifier type

  Physicians

310,728

30.24

  Pharmacists

65,062

6.33

  Other health professionals

84,365

8.21

  Patients

238,572

23.22

  Hospitals

38,922

3.79

  Lawyers

13,372

1.30

  Drugs companies

6470

0.63

  Others

124,913

12.16

  Unknown

145,001

14.11

Serious cases

  Yes

385,788

37.55

  No

300,879

29.29

  Unknown

340,738

33.16

  1. WHO, World Health Organization aQuality of reports under the age of five was uncertain and they were thus excluded